IRD

Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases

Retrieved on: 
Monday, April 11, 2022
Doctor of Science, Retina, IRD, AAV, IND, Toxicology, Visual impairment, CEO, Research Triangle Park, NMNAT1, Retinal dehydrogenase, Severe cognitive impairment, LCA5, GLOBE, RDH12, Science, Foundation, Foundation Fighting Blindness, Genetics, GMP, Patient, Pharmaceutical industry, Vaccine, Resilience, Opus

RALEIGH, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced a strategic manufacturing services agreement with National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus pipeline.

Key Points: 
  • RALEIGH, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced a strategic manufacturing services agreement with National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus pipeline.
  • Helping Opus advance their gene therapies for inherited retinal diseases to the clinic will hopefully lead to new treatments for underserved patients, said Rahul Singhvi, ScD, Chief Executive Officer of Resilience.
  • Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose.
  • Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel manufacturing scale and efficiencies.

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

Retrieved on: 
Wednesday, April 6, 2022
Risk, Retina, Heart, IRD, AAV, CNS, Liver, IgG4-related ophthalmic disease, CEO, Intravitreal injection, Tissue, Regeneron Pharmaceuticals, Collateral damage, Brain, GLOBE, Efficiency, Retinal detachment, Patient, Pharmaceutical industry, Vaccine

Under the terms of the research collaboration, Regeneron and ViGeneron will create and validate vgAAV-based therapeutic candidates for one undisclosed IRD target.

Key Points: 
  • Under the terms of the research collaboration, Regeneron and ViGeneron will create and validate vgAAV-based therapeutic candidates for one undisclosed IRD target.
  • Regeneron has an option for an exclusive license to develop, commercialize and manufacture the vgAAV-based product for the specific target.
  • ViGeneron is eligible to receive an option exercise fee, development and commercial milestone payments, plus royalties on net sales.
  • ViGenerons two novel next-generation gene therapy platforms are geared towards addressing the limitations of existing adeno-associated virus (AAV)-based gene therapies.

Quarterhill Announces Preliminary Q1 2022 Consolidated Financial Results

Retrieved on: 
Thursday, April 7, 2022
EBITDA, Mission statement, IRD, Risk, Analysis, Forward-looking statement, Perception, ITS, ETC, TSX, LLC, Quarterhill, Nota, Review, Depreciation, Ix, COVID-19, International Road Dynamics, Income, Adjustment, News, Acquisition, Disease, IFRS

TORONTO, April 7, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF), today announces an update on select preliminary consolidated financial results estimated for the three-month period ended March 31, 2022 ("Q1 2022").

Key Points: 
  • TORONTO, April 7, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF), today announces an update on select preliminary consolidated financial results estimated for the three-month period ended March 31, 2022 ("Q1 2022").
  • Driven by the anticipation of strong results from its operating subsidiaries, Quarterhill estimates its consolidated revenue for Q1 2022 to be in the range of $165-$175 million and itsconsolidated Adjusted EBITDA to be in the range of $77-$82 million.
  • Quarterhill will report its Q1 2022 financial results in early May 2022, with further details regarding its timing being made available closer to the release date.
  • These non-IFRS financial measures and non-IFRS ratios are not standardized financial measures under IFRS,and, therefore, are unlikely to be comparable to similar financial measures presented by other companies.Management believes these non-IFRS financial measures and non-IFRS ratios provide transparent anduseful supplemental information to help investors evaluate our financial performance, financial condition,and liquidity using the same measures as management.

QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB

Retrieved on: 
Thursday, March 24, 2022
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, NYSE, Research, SEC, CEO, TB, Tuberculosis, Automation, Solution, Disease, Gold, Molecular diagnostics, Knowledge, IRD, Lymphocyte, QIAGEN, Lyme disease, Pregnancy, Achievement, Death, QuantiFERON, Global, Workflow, U.S. Securities and Exchange Commission, Genetically modified bacteria, Deep Ellum, Dallas, Budget, IGRA, Life, World Health Organization, WHO, DNA, World Tuberculosis Day, QFT, Growth, World, Severe acute respiratory syndrome coronavirus 2, GDF, Review, Interferon, QGEN, Protein, Patient, Infection, LTBI, Partnership, Stop TB Partnership, BCG, Globe, Antigen, RNA, Food, Transmission, US Foods, UNITAID, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Blood, Vaccine, Pharmaceutical industry, Pharma, Insight, Academy

10 million people developed active TB disease in 2020, and they could have been identified and treated before they developed clinical symptoms and transmissible infection.

Key Points: 
  • 10 million people developed active TB disease in 2020, and they could have been identified and treated before they developed clinical symptoms and transmissible infection.
  • Today is World TB Day, a chance to remind the world that most of the 1.5 million annual deaths are avoidable.
  • The milestone of 100 million tests is an important signal on World TB Day.
  • In 2020, the World Health Organization (WHO) estimates that there were 10 million new cases of active TB worldwide and 1.5 million deaths from TB.

WiLAN and Kyocera Enter New Wireless License

Retrieved on: 
Thursday, March 31, 2022
WiLAN, IRD, Patent, Internet, Kyocera, CEO, ITS, Communication, Agreement, ETC, TSX, LLC, Industry, Intellectual property, Intelligent transportation system, International Road Dynamics, Solution, Vlădescu, Acquisition

OTTAWA, ON, March 31, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) subsidiary WiLAN Inc. ("WiLAN") today announced thatKyocera Corporationhas entered into another multi-year wireless license agreement with WiLAN.

Key Points: 
  • OTTAWA, ON, March 31, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) subsidiary WiLAN Inc. ("WiLAN") today announced thatKyocera Corporationhas entered into another multi-year wireless license agreement with WiLAN.
  • WiLAN first signed a license with Kyocera in December 2015.
  • "We are pleased Kyocera has entered into another wireless license with WiLAN," saidMichael Vladescu, WiLAN's President & CEO.
  • "The signing of this new license agreement with Kyocera further validates WiLAN's wireless patent portfolio."

IRD Marks 250th Bicycle Sensor Installation and Launches Self-Contained System at Intertraffic

Retrieved on: 
Friday, March 25, 2022
Adoption, Intelligent transportation system, AIF, Classification, IRD, OTCQX, VDS, Transport, Growth, Risk, Coronavirus, City, Research, Perception, 250th Tunnelling Company, Internet of things, CEO, ITS, TSX, Industry, Safety, Review, Forward-looking statement, Goal, Intellectual property, COVID-19, Totem, News, Engineering, Disease, Satellite navigation device, Road, IOT

The bicycle sensor systems have been installed at locations in the Netherlands, Belgium, France, Italy, Portugal and the UK.

Key Points: 
  • The bicycle sensor systems have been installed at locations in the Netherlands, Belgium, France, Italy, Portugal and the UK.
  • At the Intertraffic Amsterdam conference, IRD will unveil the "Totem" version of the TMA-3B3.
  • The self-contained system, with its own integrated pole, will make installation even easier on any road, street or path, eliminating the need for a pole or installation support.
  • "When ICOMS joined the IRD family in 2017, microwave detection products formed the foundation of all the company's offerings," said Rish Malhotra, IRD President and CEO.

WiLAN and Apple Sign License Agreement

Retrieved on: 
Tuesday, March 22, 2022
Apple Inc., WiLAN, Good, IRD, Patent, Internet, Apple, ITS, Communication, Agreement, ETC, TSX, LLC, Industry, Intellectual property, Polaris, Intelligent transportation system, International Road Dynamics, Solution, Acquisition, Online gambling

OTTAWA, ON, March 22, 2022 /PRNewswire/ -Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) subsidiary WiLAN Inc. ("WiLAN") and WiLAN's subsidiaryPolaris Innovations Limited ("Polaris") today announced a new patent license agreement (the "Agreement") with Apple Inc. ("Apple").

Key Points: 
  • OTTAWA, ON, March 22, 2022 /PRNewswire/ -Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) subsidiary WiLAN Inc. ("WiLAN") and WiLAN's subsidiaryPolaris Innovations Limited ("Polaris") today announced a new patent license agreement (the "Agreement") with Apple Inc. ("Apple").
  • The Agreement also includes the settlement and dismissal ofalllitigation pending between WiLAN and Polaris and Apple in the United States, Canada and Germany.
  • The specificconsideration payable under the Agreement and allother terms and conditions are confidential.
  • WiLAN operates in a variety of markets including automotive, digital television, Internet, medical, semiconductor and wireless communication technologies.

Quarterhill Provides Update to Q4 and Fiscal 2021 Financial Results Announcement

Retrieved on: 
Friday, March 18, 2022
IRD, ITS, ETC, TSX, LLC, Industry, Intellectual property, Intelligent transportation system, International Road Dynamics, Solution, Acquisition, Communications satellite, Retail, Civil engineering

ET on March 21, 2022, until 11:59 p.m.

Key Points: 
  • ET on March 21, 2022, until 11:59 p.m.
  • ET on March 28, 2022, at: 1.888.390.0541 (Toll Free North America) or 1.416.764.8677.
  • Quarterhill is a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (ITS) industry, as well as, through its Wi-LAN Inc. subsidiary, a leader in Intellectual Property licensing.
  • Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF.

Quarterhill to Host Virtual AGM on April 21, 2022

Retrieved on: 
Thursday, March 17, 2022
Canada Business Corporations Act, Company, Proxy, AIF, IRD, Risk, Administrator, Canadian Securities Administrators, Public health, Coronavirus, Annual general meeting, Board, Forward-looking statement, Perception, Policy, Computershare, Meeting, Health, Telephone, ITS, Board of directors, ETC, TSX, LLC, Industry, Safety, Review, Outline, Intellectual property, COVID-19, Intelligent transportation system, International Road Dynamics, Solution, News, Acquisition, Disease, Circular, AGM, Risk management, Security (finance), Management, Quarterhill

TORONTO, March 17, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF), is providing details of its upcoming Annual Meeting of shareholders ("AGM") to be held virtually on Thursday April 21, 2022, at 9:30 a.m. (Eastern Daylight Time).

Key Points: 
  • TORONTO, March 17, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF), is providing details of its upcoming Annual Meeting of shareholders ("AGM") to be held virtually on Thursday April 21, 2022, at 9:30 a.m. (Eastern Daylight Time).
  • As noted in its press release dated March 3, 2022, Quarterhill is proposing changes to its Board of Directors at the AGM.
  • Please log in 30-45 minutes prior to the start time of the AGM on April 21, 2022.
  • Quarterhill is committed to addressing all appropriate questions submitted by shareholders either live during the AGM or in advance, as timing and circumstances permit.

Quarterhill Announces Dividend

Retrieved on: 
Thursday, March 10, 2022
Industry, IRD, Director, LLC, ITS, Board, Acquisition, Intellectual property, Intelligent transportation system, Solution, TSX, ETC, International Road Dynamics, Holding company, Retail, Civil engineering

TORONTO, March 10, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) announced today that the Board of Directors has declared a quarterly dividend of $0.0125 per common share, payable on April 8, 2022, to shareholders of record at the close of business on March 18, 2022.

Key Points: 
  • TORONTO, March 10, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) announced today that the Board of Directors has declared a quarterly dividend of $0.0125 per common share, payable on April 8, 2022, to shareholders of record at the close of business on March 18, 2022.
  • Quarterhill is a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (ITS) industry, as well as, through its Wi-LAN Inc. subsidiary, a leader in Intellectual Property licensing.
  • Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF.
  • For more information, visit www.quarterhill.com